Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus LUMI SPORYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus LUMI SPORYN.
BENZAMYCIN vs LUMI-SPORYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Renal 70-80% unchanged, biliary/fecal 20-30%
Category C
Category C
Topical Antibiotic
Topical Antibiotic